ADC先導(dǎo)抗體項(xiàng)目轉(zhuǎn)讓

抗體偶聯(lián)藥物( antibody-drug conjugate,ADC) 是將單克隆抗體藥物的高特異性和小分子細(xì)胞毒藥物的高活性相結(jié)合,用以提高腫瘤藥物的靶向性、減少毒副作用。ADC抗體分子的篩選是ADC臨床轉(zhuǎn)化前的重要基礎(chǔ),是保證ADC臨床有效性和安全性的關(guān)鍵。

締碼生物針對(duì)每個(gè)ADC熱門靶點(diǎn),已經(jīng)開發(fā)出幾十種預(yù)先開發(fā)好的先導(dǎo)分子,同時(shí)建立了一整套ADC臨床前藥效學(xué)評(píng)價(jià)平臺(tái)。

pages- 1

熱門ADC先導(dǎo)抗體項(xiàng)目靶點(diǎn)

ADC先導(dǎo)抗體項(xiàng)目開發(fā)優(yōu)勢(shì)

功能活性重組蛋白

1000+ 重組ECD蛋白

200+ 全長(zhǎng)多穿膜蛋白

現(xiàn)貨先導(dǎo)抗體分子

80+ ADC先導(dǎo)抗體分子

400+ 預(yù)制B細(xì)胞種子庫

ADC 開發(fā)工具

2 評(píng)估內(nèi)吞效果的IgG標(biāo)記試劑

5 anti-payload 兔單抗

成功案例

10+ 已轉(zhuǎn)讓ADC項(xiàng)目

20+ 測(cè)試中 ADC 項(xiàng)目

ADC先導(dǎo)抗體項(xiàng)目開發(fā)流程

pages-1 5

5000+ 現(xiàn)貨先導(dǎo)抗體分子
覆蓋400+ 藥靶

pages-jiantou 1
pages-2 6

人/猴交叉反應(yīng)評(píng)估

pages-jiantou 1
pages-3 2

親和力排序

pages-jiantou2
pages-6.1

體外腫瘤細(xì)胞抑制試驗(yàn)

pages-6.2

體內(nèi)腫瘤抑制試驗(yàn)

pages-jiantou3
pages-jiantou3
pages-5改

毒素偶聯(lián)

pages-jiantou3
pages-4改

內(nèi)吞測(cè)試

案例展示

 

ADC Cell Killing Assay with MMAE conjugated GPRC5D Antibodies (Ab1 and Ab2)

pages-圖片3 2
pages- 4
pages- 5

Specific Cell Killing by Anti-GPRC5D Antibodies Conjugated with MMAE

In this experiment, three cell types were tested: K562 (negative control, left), K562-GPRC5D (positive cells, center), and H929 (GPRC5D-expressing natural cell line, right). The black and red curves represent MMAE-conjugated anti-GPRC5D antibodies (Ab1/2), showing specific killing of GPRC5D-positive cells. The blue curve represents MMAE-conjugated anti-GPRC5D positive control antibodies, and the green curve represents MMAE-conjugated IgG negative control. The data demonstrates the specific cytotoxicity of anti-GPRC5D antibodies against GPRC5D-positive cells following MMAE conjugation.

Cyno and mouse cross-reactivity tests

pages-圖片1 2

Cross-Reactivity Analysis of GPRC5D Candidate Antibodies with Cyno and Mouse GPRC5D Positive Cells Using FACS

In this study, we assessed four distinct cell types: 293T-hu GPRC5D, 293-cyno GPRC5D, 293-mouse GPRC5D, and 293T-negative control. The negative control, 293-PTT5 cells, lacked overexpressed GPRC5D proteins, while the other cells contained overexpressed GPRC5D proteins from human, cyno, and mouse species. We employed candidate antibodies, including G01~G09 (humanized antibodies developed by DIMA Bio) and G00 (a humanized antibody molecule developed by Eureka Therapeutics), to interact with these four cell types using FACS. Our data clearly reveals that G00, G05, G07, and G09 antibodies exhibit cross-reactivity with Cynomolgus Monkey GPRC5D, while the G00 antibody displays cross-reactivity with Mouse GPRC5D.

Antibody Internailzaiton Assay

reagents-ame100001 internalization of labeled gprc5d antibody flow cytometry 1

Specific Internalization of GPRC5D ADC BMK-AME100001 Conjugate in GPRC5D-Positive Cells (K562-GPRC5D Stable Expression Cell Line, Right), with No Detection in K562 Cells Lacking GPRC5D Overexpression (Left).

reagents-AME100002 Figure1 1
reagents-AME100002 Figure1 2

Specific Internalization of GPRC5D ADC BMK-AME100002 Conjugate in GPRC5D-Positive Cells (K562-GPRC5D Stable Expression Cell Line, Right), with No Detection in K562 Cells Lacking GPRC5D Overexpression (Left).

ADC payload detection

antibody-DME101004 MMAE Fig.1 Elisa 1

Figure1. Elisa plates were pre-coated with IgG-MMAE (0.2μg/per well). Serial diluted anti-MMAE monoclonal antibody (DME101004) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-MMAE monoclonal antibody binding with IgG-MMAE is 1.356ng/ml.

ADC開發(fā)工具

締碼生物致力于推動(dòng)ADC研究,并為研究人員提供所需的工具和技術(shù)服務(wù),以便于更好的定義精準(zhǔn)醫(yī)療。我們邀請(qǐng)您加入我們的變革之旅,共創(chuàng)癌癥治療的未來。

ADC 項(xiàng)目合作

依托強(qiáng)大專業(yè)的技術(shù)團(tuán)隊(duì),締碼生物可為客戶提供個(gè)性化的ADC開發(fā)服務(wù),協(xié)助客戶加快ADC藥物研發(fā)進(jìn)程。

請(qǐng)點(diǎn)擊聯(lián)系我們進(jìn)行咨詢合作!


    Please prove you are human by selecting the car。